A safety assessment of tumor necrosis factor antagonists during pregnancy

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 421-429

  Osting, Vanessa C ^a   Carter, John D ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Crohn's disease; Pregnancy; Rheumatoid arthritis; Safety; TNF antagonists

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY; VALPROIC ACID;

ADRENAL HYPERPLASIA; ANUS ATRESIA; ATRESIA; BIRTH DEFECT; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROHN DISEASE; DATA BASE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS ATRESIA; FALLOT TETRALOGY; FETUS DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HUMAN; INTESTINE MALROTATION; KIDNEY MALFORMATION; LIMB DEFECT; PREGNANCY; PRENATAL EXPOSURE; REVIEW; RHEUMATOID ARTHRITIS; SPINE MALFORMATION; SPONTANEOUS ABORTION; TERATOGENICITY; TRACHEA STENOSIS; TRACHEOESOPHAGEAL FISTULA; UNSPECIFIED SIDE EFFECT; VERTEBRA MALFORMATION;

ANIMALS; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951629894     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903578639     Document Type: Review

References (49)

1. Helmick CG, Felson DT, Lawrence RC, et al. For the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008;58(1):15-25
2. About Crohn's disease. Crohn's and Colitis Foundation of America. Available from: http://www.ccfa.org/info/about/crohns. [Last accessed 1 August 2009]
3. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheum 1983;12(2):69-72
4. Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Arthritis Rheum 1999;42(6):1219-1222
5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762-784
6. Infliximab (Remicade) package insert. Johnson & Johnson. Malvern (PA). Manufactured by Centocor, Inc: 2005. Available from: www.remicade.com
7. Etanercept (Enbrel) package insert. Amgen Wyeth. Thousand Oaks (CA). Manufactured by Immunex Corp: 2003. Available from: www.enbrel.com
8. Adalimumab (Humira) package insert. Abbott Laboratories. North Chicago (IL). Abbott Laboratories: 2005
9. Available from: www.humira.com
10. Golimumab (Simponi) package insert. Horsham (PA). Manufactured by Centocor Ortho Biotech, Inc: 2009. Available from: www.simponi.com
11. Certolizumab pegol (Cimzia) package insert. UCB, Inc. Smyrna (GA). Manufactured by UCB, Inc: 2008. Available from: www.cimzia.com
12. Nonclinical pharmacology and toxicology review of BLA 98-0286. Data on file at the FDA. Available from: http://www.fda.gov/cder/biologics/review/ etanimm110298r5.pdf [Last accessed 20 December 2007]
13. Chambers CD, Zuhre NT, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006;8:225
14. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99(12):2385-2392
15. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21(6):733-738
16. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor therapy. Rheumatology 2007;46:695-698
17. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54(6):890
18. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006;12(8):827-828
19. Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab in pregnancy. Gut 2009;58:608
20. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of literature. Joint Bone Spine 2009;76:28-34
21. Hyrich KL, Symmons DP, Watson KD, Siman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006;54(8):2701-2702
22. Ellish MH, Saboda K, O'Connor J. A prospective study of early pregnancy loss. Human Repro 1996;11(2):406-412
23. Strangfeld A, Listing J, Rau R, et al. Pregnancy outcome after exposure to biologics: results from the German biologics register RABBITT [abstract]. Arthritis Rheum 2007;56(Suppl):S311
24. Johnson DL, Jones KL, Chambers CD. Pregnancy outcomes in women exposed to adalimumab. [Abstract] Presented at the European Crohn's and Colitis Organization (ECCO) meeting in Hamburg, Germany on 6 February 2009
25. Johnson DL, Jones KL, Chambers CD. Pregnancy outcomes in women exposed to etanercept: The OTIS autoimmune disease in pregnancy project [abstract]. Available from: www.otispregnancy.org/hm/download.php?id=12&client-id[Last accessed 9 August 2009]
26. Centers for disease control and prevention (CDC). Birth defects: frequently asked questions. Available from: www.cdc.gov [Last accessed 21 March 2006]
27. Ofori B, Oraichi D, Blais L, et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77(4):268-279
28. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship? J Rheum 2006;33(5):1014-1017
29. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administrator database. J Rheumatol 2009;36:635-641
30. Salmon JE, Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 2006;54(8):2353-2355
31. Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol 1996;26(7):1527-1531
32. Glezen WP, Alpers M. Maternal immunization. Clin Infect Dis 1999;28(2):219-224
33. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of the maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-1258
34. Giroir BP, Peppel K, Silva M, Beutier B. The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw 1992;3(6):533-538
35. Toder V, Fein A, Carp H, Torchinsky A. TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet 2003;20(2):73-81
36. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009;104(1):228-233
37. Torchinsky A, Shepshelovich J, Orenstein H, et al. TNF-alpha protects embryos exposed to developmental toxicants. Am J Reprod Immunol 2003;49(3):159-168
38. Toder V, Carp H, Fein A, Torchinsky A. The role of pro-and anti-apoptotic molecular interactions in embryonic maldevelopment. Am J Reprod Immunol 2002;48(4):235-244
39. Torchinsky A, Fein A, Toder V. Teratogen-induced apoptotic cell death: does the apoptotic machinery act as a protector of embryos exposed to teratogens? Birth Defects Res C Embryo Today 2005;75(4):353-361
40. Carmichael SL, Shaw GM, Iovannisci DM, et al. Risks of human limb deficiency anomalies associated with 29 SNP's of genes involved in homocystein metabolism, coagulation, cell-cell interactions, inflammatory response, and blood pressure regulation. Am J Med Genet A 2006;140(22):2433-2440
41. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003;25(2):342-395
42. Ichiyama T, Lkada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 production and activation of NF-kappa-B. Brain Res 2000;857:246-251
43. Brent RL, Homes LB. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects? Teratology 1988;38:241-245
44. Miller MT, Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 1999;60:306-321
45. Lenz W. A short history of thalidomide embryopathy. Teratology 1988;38:203-215
46. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937
47. Garcia-Barelo MM, Wong KK, Lui VC, et al. Identification of HOXD13 mutation in a VACTERL patient. Am J Med Genet A 2008;146A(24):3181-3185
48. Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23(1):21-33
49. Mackem S, Lewandoski M. Limb development takes a measured step toward systems analysis. Sci Signal 2009;2(71):e33